[Translation] A single-center, open-label, randomized, two-cycle, two-sequence, self-crossover bioequivalence trial of a single oral dose of domperidone tablets in healthy volunteers
主要目的:以中国健康受试者为对象,考察山西宝泰药业有限责任公司生产的多潘立酮片(受试制剂,10 mg/片)与Janssen-Cilag, France生产的Motilium(参比制剂,多潘立酮片,10 mg/片)的相关药代动力学参数和相对生物利用度,评价两者在单次给药后(空腹和餐后)是否具有生物等效性。
次要目的:观察受试制剂与参比制剂在健康受试者中给药后的安全性。
[Translation] Main purpose: To investigate the domperidone tablets (test preparation, 10 mg/tablet) produced by Shanxi Baotai Pharmaceutical Co., Ltd. and Motilium (reference preparation, domperidone) produced by Janssen-Cilag, France with Chinese healthy subjects Tablets, 10 mg/tablet) related pharmacokinetic parameters and relative bioavailability, to evaluate whether the two are bioequivalent after a single dose (fasting and meal).
Secondary objective: To observe the safety of the test product and the reference product after administration in healthy subjects.